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Juvenile idiopathic arthritis (JIA) reflects a group of clinically heterogeneous, autoimmune 
disorders in children characterized by chronic arthritis and hallmarked by elevated 
levels of circulating immune complexes (CICs) and associated complement activation 
by-products in their sera. Immune complexes (ICs) have been detected in patients’ 
sera with JIA utilizing a variety of methods, including the anti-human IgM affinity col-
umn, C1q solid-phase assay, polyethylene glycol precipitation, Staphylococcal Protein 
A  separation method, anti-C1q/C3 affinity columns, and FcγRIII affinity method. As 
many as 75% of JIA patients have had IC detected in their sera. The CIC proteome 
in JIA patients has been examined to elucidate disease-associated proteins that are 
expressed in active disease. Evaluation of these ICs has shown the presence of multiple 
peptide fragments by SDS-PAGE and 2-DE. Subsequently, all isotypes of rheumatoid 
factor (RF), isotypes of anti-cyclic citrullinated peptide (CCP) antibodies, IgG, C1q, C4, 
C3, and the membrane attack complex (MAC) were detected in these IC. Complement 
activation and levels of IC correlate with disease activity in JIA, indicating their role in the 
pathophysiology of the disease. This review will summarize the existing literature and 
discuss the role of possible protein modification that participates in the generation of the 
immune response. We will address the possible role of these events in the development 
of ectopic germinal centers that become the secondary site of plasma cell development 
in JIA. We will further address possible therapeutic modalities that could be instituted as 
a result of the information gathered by the presence of ICs in JIA.
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Juvenile idiopathic arthritis (JIA) is a protean disorder, whose variable modes of onset and patterns 
of disease course are accompanied by a myriad of diverse signs, symptoms, and manifestations. It is 
defined by seven basic subgroups, of which polyarticular-onset rheumatoid factor (RF) positive and 
negative, oligoarticular-onset, and systemic-onset are the most common onset types (1). Most recent 
studies show many immune abnormalities characteristic of the disease (2).
eARLY STUDieS
Immune complexes (IC) have been described for many years in patients with JIA. Gabriel and Agnello 
first found IC in 40% of patients with JIA by the C1q inhibition test and in 24% by the monoclonal RF 
assay (3). Subsequently, Rossen et al., utilizing the C1q binding assay (C1qBA), reported IC in 22% of 
children with JIA and their presence correlated with more severe disease (4). Miller et al., using the 
C1qBA, found IC in 66% with systemic-onset, 38% in polyarticular-onset, but only 14% positive with 
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oligoarticular-onset. This study indicated IC presence correlated 
with 19S IgM RF and activation products of complement, C3c 
and C3d in these patients with JIA (5). We, subsequently, assayed 
53 children with JIA for IC by four different methods, C1q solid-
phase assay (C1qSPA), 2% polyethylene glycol precipitation assay 
(PEGPA), Raji cell assay (RCA), and the conglutinin assay (KA). 
Seventy-nine percent of JIA patients demonstrated elevated IC 
levels by at least one method. By the C1qSPA, 58% were positive, 
50% by the RCA, 37% by the KA, but 0% by the PEGPA method. 
The C1qSPA demonstrated the most elevated levels of IC in all 
three onset types. The elevated levels correlated with the presence 
of 19S IgM RF, hidden 19S IgM RF (complexes seen in JIA), and 
active disease. The correlation with disease activity indicated for 
the first time that IC may play an active role in the pathophysiol-
ogy of JIA. The study, also, demonstrated that the C1qSPA was the 
best assay for measuring IC in the sera of JIA patients (6).
We, subsequently, subjected 10 JIA patients’ sera to affinity 
chromatography on a rabbit anti-human IgM column eluting 
with 1 M ammonia and 0.1 M glycine–HCl buffer, pH 3.0, and 
15 patients to 4% PEG precipitation followed by acid dissociation 
of the precipitate. The majority (80%) of the fractions contained 
IgM RF and IgG, indicating IC. The sera were then subjected to 
sucrose density gradient (SDG) centrifugation and the resultant 
fractions analyzed for the presence of IC by the C1qSPA. IC were 
detected at and ahead of the IgM marker, as expected for IgM RF–
IgG complexes (7). A further study isolated IC in JIA patients by 
the use of immunoabsorbent columns. The IgG fraction obtained 
by DEAE 50 separation of rabbit anti-human C1q (αHC1q) 
and goat anti-human C3 (αHC3) antiserum were dialyzed over 
night against 0.1 M NaHCO3 with 0.5 M NaCl, pH 8.3. Finally, 
the rabbit IgG αHC1q and goat IgG αHC3 were digested with 
pepsin. The F(ab′)2 fragments were isolated by gel filtration on 
Sephadex G-200 a in 0.15 M PBS pH 7.4 at room temperature. 
Cyanogen bromide activated Sepharose 4B was swelled and 
bound to the F(ab′)2 fragments of the IgG fractions of αHC1q 
and αHC3. One milliliter of the patient’s serum was added to the 
column with 1 ml of 8% PEG in veronal buffer and incubated for 
2 h. The mixtures were centrifuged for 1 h. The precipitates were 
resuspended in 1 ml of veronal buffer and applied to the columns 
for 60 min at room temperature. The columns were sequentially 
eluted. The majority again showed IgM RF, IgG, and IgG RF in 
a smaller percentage. On SDG analysis, all IC demonstrated in 
the peaks >19S, complement-fixing 19s IgM RF, IgG, and IgG RF 
containing IC, which proved they can be detected in the serum 
of JIA patients (8). Furthermore, more sophisticated studies 
were performed to isolate IC in JIA patients’ sera. JIA sera was 
evaluated by separation on a Sepharose 4B column to which were 
bound F(ab′)2 fragments of goat IgG anti-human IgM antibody 
to separate IgM-containing IC. The columns were sequentially 
eluted and the isolated fractions were assayed for 19S IgM RF and 
7S IgG RF by enzyme-linked immunoabsorbent assay (ELISA), 
IgG levels by immunodiffusion, and by preparative isoelectric 
focusing (PIEF). The eluates revealed in the ammonia fraction 
IgM RF in 25% and IgG RF in 16%, all polyarticular-onset JIA 
patients. In the acid fraction, 67% demonstrated 19S IgM RF and 
IgG, including both six RF-positive and six RF-negative polyar-
ticular patients and in three oligoarticular patients. IgG RF was 
also detected in six polyarticular patients. Analysis by PIEF of the 
IgM RF and IgG RF-positive ammonia and acid fractions showed 
IgM RF throughout the pH range (4–10), but the highest amount 
of IgM RF were detected only in the restricted spectrotypic area 
of pH 4.0–5.5. This was the area where only IgG RF was detected. 
These studies demonstrated IC containing 19S IgM RF-IgG and 
19S IgM RF-7S IgG RF can be detected in JIA sera and predomi-
nately found in the pH band 4.0–5.5 by IEF. These complexes that 
were detected correlated with active disease. This study laid the 
groundwork for further defining individual constituents of the IC 
found in JIA patients (9).
Jarvis et  al. (10) investigated further the complement sys-
tem and IC in JIA by examining plasma levels of complement 
activation fragments C4d and Bb. However, they could find no 
strong correlations between IC levels and complement activation 
products. This suggested that plasma complement activation is a 
concomitant of active disease in JIA (10).
LATeR STUDieS
Subsequent studies were outlined to build on the previous findings 
to try to determine the possible constituents of these IC. Sera from 
104 patients with JIA were separated on a Sepharose 4B column 
to which were bound F(ab′)2 fragments of goat anti-human IgM 
antibody. The column was sequentially eluted with 1 M ammonia 
and 0.1  M glycine-HCl buffer, pH 3. The eluted material was 
treated with sodium dodecyl sulfate (SDS) and simultaneously 
reduced with 2-mercaptoethanol. Individual components were 
then separated by SDS-gradient polyacrylamide gel electropho-
resis (PAGE) and were transferred to nitrocellulose by Western 
blotting overlaid with the patient’s own serum and developed 
with specific antiserum to human IgM and IgG. Four bands were 
noted in the majority of JIA patients, one in the 70–80 kDa area 
corresponding to the IgM heavy chain and in the 50 kDa area 
to the IgG heavy chain. Additional bands specific for JIA were 
detected in the 40 and 60 kDa areas. Sixty percent of JIA patients 
showed all four bands and about 80% showed the 40 kDa band 
and 70% the 60 kDa band. These band findings indicated further 
the presence of IC in JIA contained IgM RF, IgG RF, and IgG and 
possibly heat shock proteins (11).
Further studies indicated that circulating IC in JIA have the 
potential to interact with resident joint synovial fibroblasts (syn-
oviocytes) and induce the expression of inflammatory cytokines. 
Cultures of normal synoviocytes were treated with IC from the 
sera of JIA patients that contained IgM RF, C1q, IgG, and C3. 
These IC induced IL-8 mRNA and protein production. These data 
further indicate that C1q in these IC mediates IL-8 induction in 
synoviocytes, playing a key role in the inflammation in the JIA 
synovium and contributing to disease (12).
Our group subsequently evaluated further IC in JIA patients 
by attempting to assess B-cell activity by measuring the amount 
of and the κ:λ immunoglobulin light (L) chain ratio in IC and to 
determine potential evidence for either an antigen-driven response 
or B-cell receptor editing. An ELISA was used to measure κ and 
λ chains present in the IC. The κ:λ light chain ratio was reversed 
among JIA patients with a λ predominance in RF-positive pol-
yarthritis, RF-negative polyarthritis, oligoarticular patients, and 
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systemic-onset patients. This demonstrated preferential selection 
of λ chains contributing to the formation of potentially pathogenic 
IC in JIA patients. This also indicated the potential for L chain 
editing and a marker for increased B-cell activity in JIA (13).
ReCeNT STUDieS
We next evaluated the circulating IC proteome in JIA patients 
by trying to elucidate disease-associated proteins that were over-
expressed in JIA patients with aggressive disease and erosions 
by X-ray. IC were isolated from the sera of patients with erosive 
disease or active, early, aggressive disease subsequent to protein 
separation by 2-DE. Thirty-seven protein spots were overex-
pressed in the IC from the patients with aggressive disease. These 
included proteolytic fragments of glyceraldehyde-3-phosphate 
dehydrogenase, serotransferrin, and α-1-antityrpsin. These 
disease-associated proteins most definitely contribute to forma-
tion of IC and likely have a significant role in disease etiology and 
pathogenesis. This was the first in-depth analysis of circulating IC 
in JIA (14). To further evaluate the IC from sera of patients with 
JIA, we measured activated complement products bound to the 
circulating IC. Sera from 100 patients with JIA were evaluated for 
C1q, C4, C3, C3d, and membrane attack complex (MAC) bound 
to IC by ELISA. JIA patients had elevated levels of complement 
components bound to their IC, particularly from the classical 
pathway. This supports the notion of complement-mediated 
tissue injury that is triggered by IC-mediated classical pathway 
activation in JIA (15).
Our group subsequently looked at IC constituents through 
evaluating antibodies to multiple citrullinated epitopes present 
in the sera of patients with various subtypes of JIA. These studies 
demonstrated the frequent occurrence of anti-citrullinated type 
II collagen and anti-citrullinated fibrinogen antibodies (16, 17). 
Further studies also demonstrated isotypes of α-enolase could 
also be found in the serum of children with JIA (18).
These studies indicated that citrullinated autoantibody isotype 
diversity may indicate a more severe disease course in JIA patients. 
Complement activation and levels of IC overall correlate with dis-
ease activity in JIA, indicating their role in the pathophysiology 
of the disease. These events in protein modification participate in 
the generation of an immune response and the possible develop-
ment of ectopic germinal centers that become the secondary site 
of plasma cell development in JIA. These results indicate that the 
presence of IC in JIA and especially those containing RF and anti-
cyclic citrullinated peptide (CCP) antibody isotypes signify more 
aggressive disease and earlier intervention with immunomodula-
tors and biologics in the treatment of their disease.
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